Richter F, Mikulik O, Ebersberger A, Schaible HG. Noradrenergic agonists and antagonists influence migration of cortical spreading depression in rat - a possible mechanism of migraine prophylaxis and prevention of postischemic neuronal damage. J Cereb Blood Flow Metab 2005; 25 (9): 1225-1235.
Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, Kwong KK, Cutrer FM, Rosen BR, Tootel RB, Sorensen AG, Moskowitz MA. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA 2001; 98: 4687-4692.
Woods RP, Iacoboni M, Mazziotta JC. Brief report: Bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. New Eng J Med 1994; 331: 1689-1692.
Géraud E, Denuelle M, Fabre N, Payoux P, Chollet F. Positron emission tomographic studies of migraine. Rev Neurol (Paris) 2005; 161: 666-670.
Schoenen J, Jamart B, Delwaide PJ. Cartographie électroencé-phalographique dans les migraines en périodes critique et intercritique. Rev EEG Neurophysiol Clin 1987; 17: 289-299.
Ebersberger A, Schaible HG, Averbeck B, Richter F. Is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? Ann Neurol 2001; 49 (1): 7-13.
Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002; 8 (2): 136-42.
van den Maagdenberg AM, Pietrobon D, Pizzorusso T, Kaja S, Broos LA, Cesetti T, van de Ven RC, Tottene A, van der Kaa J, Plomp JJ, Frants RR, Ferrari MD. A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression. Neuron 2004; 41 (5): 701-710.
Fumal A, Schoenen J. Genetics of migraines: From ionic channels to single nucleotide polymorphisms? Rev Med Liège 2004; 59: 367-377.
Akerman S, Goadsby PJ. Topiramate inhibits cortical spreading depression in rat and cat: Impact in migraine aura. Neuroreport 2005; 16 (12): 1383-1387.
Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: A randomized controlled trial. Neurology 1998; 50: 466-470.
Boehnke C, Reuter U, Flach U, Schuh-Hofer S, Einhaupl KM, Arnold G. High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur J Neurol 2004; 11 (7): 475-477.
Sándor PS, Áfra J, Ambrosini A, Schoenen J. Prophylactic treatment of migraine with beta-blockers and riboflavin: Differential effects on the intensity dependence of auditory evoked cortical potentials. Headache 2000; 40: 30-35.
Smith ME, Gevins A, McEvoy LK, Meador KJ, Ray PG, Gilliam F. Distinct cognitive neurophysiologic profiles for lamotrigine and topiramate. Epilepsia 2006; 47 (4): 695-703.
D'Andrea G, Granella F, Cadaldini M, Manzoni GC. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: An open pilot study. Cephalalgia 1999; 19: 64-66.
Lampl C, Katsarava Z, Diener H-C, Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry 2005; 76: 1730-1732.
Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997; 17: 109-112.
Shields KG, Goadsby PJ. Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: A role in migraine? Brain 2005; 128: 86-97.
Tfelt-Hansen P, Mathew NT. General and pharmacological approach to migraine management. In: Olesen J, Goadsby P, Ramadan N, Tfelt-Hansen P, eds., The headaches. Chap 47, 3rd ed. Amsterdam: K.M.A. Welch. Elsevier, pp. 2005.
Bradley DP, Smith MI, Netsiri C, Smith JM, Bockhorst KHJ, Hall LD, Huang CL-H, Leslie RA, Parsons AA, James MF. Diffusion-weighted MRI used to detect in vivo modulation of cortical spreading depression: Comparison of sumatriptan and tonabersat. Exp Neurol 2001: 172: 342-353.
May A, Bahra A, Buchel C, Frackowiak RSJ, Goadsby PJ. Hypothalamic activation in cluster headache attacks. Lancet 1998; 352: 275-278.
Peres MF, Sanchez del Rio M, Seabra S, Tufik ML, Abucham S, Cipolla-Neto J, Silberstein SD, Zukerman E. Hypothalamic involvement in chronic migraine. J Neurol Neurosurg Psychiatry 2001; 71: 747-751.
Fumal A, Laureys S, Di Clemente L, Boly M, Bohotin V, Vandenheede M, Coppola G, Salmon E, Kupers R, Schoenen J. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain 2006; 129: 543-550.
Radat F, Creac'h C, Swendsen JD, Lafittau M, Irachabal S, Dousset V, Henry P. Psychiatric comorbidity in the evolution from migraine to medication overuse headache. Cephalalgia 2005; 25: 519-522.
Volkow ND, Fowler JS, Wang GJ. The addicted human brain viewed in the light of imaging studies: Brain circuits and treatment strategies. Neuropharmacology 2004; 47: 3-13.
Tao R, Ma Z, Mckenna JT, Thakkar MM, Winston S, Strecker RE, McCarly RW. Differential effect of orexins (hypocretins) on Serotonin release in the dorsal and median raphe nuclei of freely behaving rats. Neuroscience 2006; 141: 1101-1105.